As­traZeneca's $40M deal with Al­lo­ri­on; Apol­lo rais­es $33M; Xo­ma's stock buy­back

An­oth­er Chi­na-US deal for As­traZeneca: The British drug­mak­er is pay­ing $40 mil­lion up­front to Al­lo­ri­on Ther­a­peu­tics to de­vel­op the com­pa­ny’s L858R mu­tat­ed al­losteric in­hibitor as a po­ten­tial treat­ment for EGFR-mu­tant non-small cell lung can­cer. The agree­ment al­so in­cludes more than $500 mil­lion in mile­stones. Last week, As­traZeneca an­nounced plans to buy Gra­cell Biotech­nolo­gies for $1 bil­lion.

Apol­lo Ther­a­peu­tics raised an ad­di­tion­al $33.5 mil­lion, bring­ing its Se­ries C round to $260 mil­lion. The fi­nanc­ing, which was led by Pa­tient Square Cap­i­tal, is ex­pect­ed to help progress Apol­lo’s pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER